Blisibimod

Drug Profile

Blisibimod

Alternative Names: A-623; AMG-623

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen
  • Developer Anthera Pharmaceuticals
  • Class Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - IgA nephropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • Phase II IgA nephropathy
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 09 Aug 2017 Blisibimod receives Orphan Drug status for IgA nephropathy in USA
  • 14 Jun 2017 Efficacy and adverse events data from the phase III CHABLIS-SC1 trial in Systemic lupus erythematosus presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 27 Feb 2017 Anthera Pharmaceuticals terminates the phase III CHABLIS 7.5 trial for Systemic lupus erythematosus in Georgia (NCT02514967)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top